Junghans RP - Search Results

1

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

Junghans RP. Junghans RP. Immunol Res. 1997 Feb;16(1):29-57. doi: 10.1007/BF02786322. Immunol Res. 1997. PMID: 9048207 Review.

2

Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.

Ma Q, DeMarte L, Wang Y, Stanners CP, Junghans RP. Ma Q, et al. Among authors: junghans rp. Cancer Gene Ther. 2004 Apr;11(4):297-306. doi: 10.1038/sj.cgt.7700685. Cancer Gene Ther. 2004. PMID: 15002034

3

Functional analysis of the mouse Fcgrt 5' proximal promoter.

Tiwari B, Junghans RP. Tiwari B, et al. Among authors: junghans rp. Biochim Biophys Acta. 2005 Jan 11;1681(2-3):88-98. doi: 10.1016/j.bbaexp.2004.10.002. Epub 2004 Nov 24. Biochim Biophys Acta. 2005. PMID: 15627500

4

The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile.

Telleman P, Junghans RP. Telleman P, et al. Among authors: junghans rp. Immunology. 2000 Jun;100(2):245-51. doi: 10.1046/j.1365-2567.2000.00034.x. Immunology. 2000. PMID: 10886402 Free PMC article.

5

An optimized method for cell-based phage display panning.

Watters JM, Telleman P, Junghans RP. Watters JM, et al. Among authors: junghans rp. Immunotechnology. 1997 Mar;3(1):21-9. doi: 10.1016/s1380-2933(96)00056-5. Immunotechnology. 1997. PMID: 9154465

6

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

Junghans RP, Anderson CL. Junghans RP, et al. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5512-6. doi: 10.1073/pnas.93.11.5512. Proc Natl Acad Sci U S A. 1996. PMID: 8643606 Free PMC article.

7

Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.

Junghans RP, Waldmann TA. Junghans RP, et al. J Exp Med. 1996 Apr 1;183(4):1587-602. doi: 10.1084/jem.183.4.1587. J Exp Med. 1996. PMID: 8666917 Free PMC article.

8

Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies.

Junghans RP, Carrasquillo JA, Waldmann TA. Junghans RP, et al. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1752-7. doi: 10.1073/pnas.95.4.1752. Proc Natl Acad Sci U S A. 1998. PMID: 9465089 Free PMC article.

9

Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.

Junghans RP, Dobbs D, Brechbiel MW, Mirzadeh S, Raubitschek AA, Gansow OA, Waldmann TA. Junghans RP, et al. Cancer Res. 1993 Dec 1;53(23):5683-9. Cancer Res. 1993. PMID: 8242624

10

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

Koon HB, Severy P, Hagg DS, Butler K, Hill T, Jones AG, Waldmann TA, Junghans RP. Koon HB, et al. Among authors: junghans rp. Leuk Res. 2006 Feb;30(2):190-203. doi: 10.1016/j.leukres.2005.06.007. Epub 2005 Sep 13. Leuk Res. 2006. PMID: 16165209

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results